BioNTech sees differentiation in OncoC4’s CTLA-4, commits $200M up front

An early clinical readout for OncoC4’s anti-CTLA-4 antibody has helped drive a deal that gives BioNTech rights to the program for $200 million up front.

BioNTech SE (NASDAQ:BNTX) will receive exclusive, worldwide rights to ONC-392, which is in Phase I/II testing as monotherapy and in combination with Keytruda pembrolizumab to treat solid tumors, including melanoma and lung and ovarian cancers. The deal includes milestones and royalties of undisclosed size due to OncoC4 Inc...